Seres Therapeutics price target lowered to $8 from $10 at Chardan

Chardan lowered the firm’s price target on Seres Therapeutics to $8 from $10 and keeps a Buy rating on the shares post the Q4 report. The lower price target reflects a higher projected future share count as modeled future capital raises are expected to be more dilutive due to the current lower share price, the analyst tells investors in a research note.